Location
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, Colorado
Hotel Phone: (303) 436-1234
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
Meeting Room
Capitol Ballroom (Fourth Floor)
Faculty Christopher Flowers, MD, MS
Division Head, Division of Cancer Medicine
Chair, Professor Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Manali Kamdar, MD, MBBS
Associate Professor
Clinical Director of Lymphoma Services
Morton and Sandra Saffer Endowed Chair in Hematology Research
Division of Hematology, Hematologic Malignancies
University of Colorado Cancer Center
Aurora, Colorado
Robin Klebig, MSN, APRN, CNP, AOCNP
Hematology Outpatient APP Supervisor
Assistant Professor of Medicine
Nurse Practitioner, Lymphoma Group
Division of Hematology
Mayo Clinic
Rochester, Minnesota
Additional faculty to be announced.
Meeting space has been assigned to provide a satellite symposium supported by ADC Therapeutics and AstraZeneca Pharmaceuticals LP during the Oncology Nursing Society’s (ONS) 50th Annual Congress, April 9-13, 2025 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
Program Schedule — Mountain Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting
MODULE 1: Role of Polatuzumab Vedotin in Therapy for Diffuse Large B-Cell Lymphoma (DLBCL)
Structural components and mechanism of antitumor activity of polatuzumab vedotin
Published results with polatuzumab vedotin in combination with chemotherapy for previously untreated DLBCL
Status of polatuzumab vedotin as a component of up-front DLBCL therapy; impact of cell of origin and other patient- and disease-related factors on the selection of candidates for this strategy
Long-term findings with polatuzumab vedotin in combination with bendamustine/rituximab (BR) for patients with relapsed/refractory (R/R) DLBCL
Rates of peripheral neuropathy and other treatment-emergent adverse events (AEs) observed with polatuzumab vedotin in the up-front and R/R settings; appropriate monitoring and management strategies
MODULE 2: Incorporating Tafasitamab/Lenalidomide into the Management of DLBCL
Mechanism of action of tafasitamab and biological rationale for its use in combination with lenalidomide for DLBCL
Key data leading to the FDA approval of tafasitamab/lenalidomide for R/R DLBCL
Optimal sequencing of tafasitamab/lenalidomide for individual patients with R/R DLBCL
Safety considerations with tafasitamab; strategies to address cytopenias and other commonly occurring AEs
MODULE 3: Role of Loncastuximab Tesirine in Treatment for Patients with R/R DLBCL
Mode of activity and structural makeup of the anti-CD19 antibody-drug conjugate loncastuximab tesirine
Principal efficacy and safety findings with loncastuximab tesirine for patients with R/R DLBCL
Patient selection for treatment with loncastuximab tesirine
Incidence, severity and management of commonly occurring AEs with loncastuximab tesirine, such as edema, effusion, myelosuppression, and cutaneous reactions
MODULE 4: Current and Future Use of Covalent Bruton Tyrosine Kinase (BTK) Inhibitors in the Management of Mantle Cell Lymphoma (MCL)
Long-term outcomes achieved with currently available approaches to first-line therapy for younger and older patients with MCL; rationale for the investigation of BTK inhibition in this setting
Published data with ibrutinib as a component of up-front therapy for older and younger patients with MCL
Efficacy and safety outcomes supporting the recent FDA approval of acalabrutinib in combination with BR as first-line therapy for transplant-ineligible patients with MCL
Available research findings with BTK inhibitors without chemotherapy in the up-front and relapsed settings; current role of BTK inhibitor monotherapy or in combination with an anti-CD20 antibody
Key efficacy and safety results with the addition of venetoclax to BTK inhibitors for patients with MCL; implications for clinical practice and ongoing research
MODULE 5: Tolerability of BTK Inhibitors
Available data documenting the comparative tolerability of ibrutinib, acalabrutinib and zanubrutinib
Risk factors for and reported incidence and severity of cardiac arrhythmias and other cardiovascular toxicities with ibrutinib, acalabrutinib and zanubrutinib
Spectrum and incidence of clinically relevant nonhematologic toxicities, including arthralgias/myalgias, gastrointestinal (GI)-related events, cytopenias, infections and rash with BTK inhibitors
Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving BTK inhibitors
Impact on the tolerability of BTK inhibitors when administered in combination with other systemic therapies (eg, chemoimmunotherapy, venetoclax) for MCL
MODULE 6: Role of the Noncovalent BTK Inhibitor Pirtobrutinib in the Treatment of R/R MCL
Pharmacologic similarities and differences between covalent and noncovalent BTK inhibitors
Antitumor activity documented with pirtobrutinib for patients with R/R MCL, including among those with disease progression on covalent BTK inhibitors
Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
FDA approval and current clinical role of pirtobrutinib in treatment for R/R MCL
MODULE 7: Utility of Tazemetostat in Treatment for Follicular Lymphoma (FL)
Incidence of EZH2 mutations in patients with FL; optimal timing and methods for EZH2 mutation testing
Key clinical trial findings with tazemetostat for previously treated FL
Appropriate selection of patients with and without EZH2 mutations for treatment with tazemetostat
Tolerability profile of tazemetostat for FL; educating patients regarding the risk for common complications, such as fatigue, infection, musculoskeletal pain and GI events, and rare but serious complications, such as secondary cancers
MODULE 8: Other Available and Emerging Novel Therapies for R/R FL
Published data supporting the FDA approval of zanubrutinib/obinutuzumab for R/R FL and clinical role of this approach in treatment
Biological rationale for targeting CD19 with tafasitamab for indolent lymphomas
Emerging efficacy and safety findings with the addition of tafasitamab to lenalidomide/rituximab for patients with R/R follicular or marginal zone lymphoma; potential clinical role
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma.
Learning Objectives
Upon completion of this activity, participants should be able to
Identify patients with newly diagnosed DLBCL for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate.
Understand published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in treatment for DLBCL and FL, and employ this information in patient education discussions.
Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates in therapy for patients with R/R DLBCL.
Evaluate published clinical research findings establishing the efficacy and safety of BTK inhibitors as a component of first-line therapy for MCL, and assess the current and potential role of various BTK inhibitor-based strategies in the care of patients newly diagnosed with the disease.
Appreciate the biological rationale for, available data with and current clinical role of BTK inhibitors in treatment for patients with R/R MCL, and discern how these agents can be appropriately and safely integrated into routine practice.
Review published clinical research findings establishing the efficacy and safety of combined BTK inhibitor/anti-CD20 antibody therapy for R/R FL, and identify patients for whom treatment with available combinations would be appropriate.
Recognize the spectrum, frequency and severity of adverse events associated with various therapies commonly employed in the care of patients with non-Hodgkin lymphoma, and consider recommended approaches to prevent, ameliorate and manage resultant side effects.
Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2025/NHL/ILNA
Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.
Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Ms Klebig has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Flowers — Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.
Dr Kamdar — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: Novartis; Data and Safety Monitoring Boards/Committees: Celgene Corporation, Genentech, a member of the Roche Group.
Additional faculty to be announced.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from ADC Therapeutics and AstraZeneca Pharmaceuticals LP.
Hyatt Regency Denver at Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room
Capitol Ballroom (Fourth Floor)
The Hyatt Regency Denver at Colorado Convention Center is the headquarters hotel for the 2025 ONS Congress and is adjacent to the Colorado Convention Center.
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma.
There is no registration fee for this event. For the in-person symposium in Denver, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for the 2025 ONS Congress.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
